[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@ArndtVogel Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1211086357.png) @ArndtVogel Arndt Vogel

Arndt Vogel posts on X about matterhorn, iii, os, ctx the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1211086357/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211086357/c:line/m:interactions.svg)

- X Week XXXXXX +1,821%
- X Month XXXXXX +280%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%

### Mentions: XX [#](/creator/twitter::1211086357/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211086357/c:line/m:posts_active.svg)

- X Year XX -XXXX%

### Followers: XXXXX [#](/creator/twitter::1211086357/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211086357/c:line/m:followers.svg)

- X Week XXXXX +1.30%
- X Month XXXXX +1.90%
- X Months XXXXX +10%
- X Year XXXXX +24%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1211086357/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1211086357/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1211086357/influence)
---

**Social category influence**
[currencies](/list/currencies)  [cryptocurrencies](/list/cryptocurrencies)  [travel destinations](/list/travel-destinations) 

**Social topic influence**
[matterhorn](/topic/matterhorn), [iii](/topic/iii), [os](/topic/os), [ctx](/topic/ctx) #8, [pts](/topic/pts)
### Top Social Posts [#](/creator/twitter::1211086357/posts)
---
Top posts by engagements in the last XX hours

"MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: XX% MPR: XX% any: XX% 👉 OS: HR: 0.78; 36-mo OS: XX vs XX% 🧐OS improved independent of TAP better in responders new SOC @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979158577697747093) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-17T12:12Z 8829 followers, 15.4K engagements


"CS1003-305 phs-3: Nofazinlimab + lenvatinib vs plc + lenvatinib as 1L treatment for HCC #ESMO25 #ESMOAmbassadors 👉 ORR: XX vs XX% 👉 mPFS: XXX vs XXX mo 👉 mOS: XXXX vs XXXX mo 🧐As in LEAP-002 trend for better outcomes but negative trial @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979478162200252792) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T09:22Z 8807 followers, 1648 engagements


"IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II: Durvalumab plus tremelimumab in advanced BTC after failure of platinum-based CTx #ESMO25 #ESMOAmbassadors 👉 ICI is now SOC in 1L no convincing single for dual ICI in 2L but there are some ICI responder 👉we need biomarkers @myESMO"  
[X Link](https://x.com/ArndtVogel/status/1980202790564868298) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:21Z 8811 followers, 1996 engagements


"PRODIGE 81/FFCD 2101 - TRIPLET HCC: Adding IPI to ATEZO + BEV in 1L uHCC #ESMO25 #ESMOAmbassadors 👉ORR: XX vs XXXX% 👉mPFS: XXX vs XXX mo 👉mOS: CC vs XX mo 🧐No benefit for adding IPI surprisingly clear negative.not enough anti-CTL4 @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979479438774452412) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T09:27Z 8816 followers, 6157 engagements


"Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2 #ESMO25 #ESMOAmbassadors 👉 patient based comparison 👉 Final coffin nail for CTx 👉 Can we omit surgery next 🧐 Amazing efficacy for ICI in MSI CRC @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979536022305468468) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T13:12Z 8829 followers, 5170 engagements


"PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: XX (-) vs XX% (+) 🧐Very innovative trail design ctDNA guided ACT is the future @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979531991625367833) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-18T12:56Z 8829 followers, 10.9K engagements


"CARES-009: Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs XX mo 👉 DFS: XX vs XX mo 👉 MPR: XX vs X% 🧐Very promising results neoadjuvant strategies will be the future in HCC @myesmo @EASLedu @ilca"  
[X Link](https://x.com/ArndtVogel/status/1979850194520047944) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-19T10:00Z 8829 followers, 9591 engagements


"HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D PDAC #ESMO25 #ESMOAmbassadors 👉 ORR: XX% DCR XX% 👉 6mo PFS rate: XX% 👉 manageable safety 🧐 KRASi are the future in 1L @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1979954921983394196) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-19T16:56Z 8829 followers, 5176 engagements


"TALENTop phs 3: Liver resection versus continued atezolizumab plus bevacizumab in locally advanced HCC after atezo/bev treatment #ESMO25 #ESMOAmbassadors 👉 EFS: XX vs vs XX mo 🧐great study design: response adapted subsequent therapy. Multimodal therapy in HCC is key @myesmo @EASLedu @ILCAnews"  
[X Link](https://x.com/ArndtVogel/status/1980200970685481008) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:14Z 8829 followers, 3330 engagements


"Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX in Resectable High-Risk iCCCA: Phase II-III Trial #ESMO25 #ESMOAmbassadors 👉 EFS: X vs 18mo 🧐Strong signal for neoadjuvant therapy in BTC more trials to come. @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980204184827031608) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:27Z 8829 followers, 6066 engagements


"CASSANDRA phs 3: short vs long-course pre-operative CTx for stage I-III PDAC #ESMO25 #ESMOAmbassadors 👉 No difference in EFS between short vs long pre-OP CTx 👉but high CA19.9 response N0 resection dose intensity 🧐the jury is still out for best neoadjuvant approach @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980206290300481756) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T09:35Z 8829 followers, 4312 engagements


"🔥Presidential Session🔥 AGITG DYNAMIC-III trial : ctDNA-guided adjuvant CTx de-escalation in stage III CRC analysis of the ctDNA-cohort #ESMO25 #ESMOAmbassadors 👉 markedly reduced oxaliplatin exposure 👉 non-inferiority not shown specifically in high risk pts 👉 ctDNA burden prognostic 🧐feasible but not yet there.predictive uncertainty @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980291243868344735) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T15:13Z 8829 followers, 4289 engagements


"🔥Presidential Session🔥 FORTITUDE-101 phase III: Bemarituzumab plus CTx for advanced FGFR2b+ G/GEJC #ESMO25 #ESMOAmbassadors 👉mOS:17.9 vs XXXX mo but less benefit w/ follow up 👉Ocular AEs may be a concern 🧐Positive trial but not practice changing 👏great discussion by @YJanjigianMD @myesmo"  
[X Link](https://x.com/ArndtVogel/status/1980306502188474585) [@ArndtVogel](/creator/x/ArndtVogel) 2025-10-20T16:13Z 8829 followers, 7128 engagements